REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $35.27.

A number of analysts recently commented on RGNX shares. Royal Bank of Canada reissued an "outperform" rating and set a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. Morgan Stanley reissued an "overweight" rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research note on Wednesday, November 20th. HC Wainwright dropped their target price on shares of REGENXBIO from $40.00 to $36.00 and set a "buy" rating for the company in a report on Thursday, November 21st. Finally, Raymond James restated an "outperform" rating and set a $18.00 price objective on shares of REGENXBIO in a research report on Thursday, October 10th.

Institutional Trading of REGENXBIO

A number of hedge funds have recently added to or reduced their stakes in the business. Redmile Group LLC raised its position in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company's stock worth $51,327,000 after buying an additional 323,100 shares during the period. Geode Capital Management LLC raised its holdings in REGENXBIO by 4.2% in the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company's stock valued at $11,422,000 after buying an additional 44,037 shares during the period. Integral Health Asset Management LLC lifted its position in REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after buying an additional 190,000 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock worth $4,382,000 after buying an additional 37,055 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of REGENXBIO by 9.3% in the second quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company's stock worth $3,972,000 after acquiring an additional 28,846 shares in the last quarter. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Up 5.4 %

RGNX stock traded up $0.42 on Monday, reaching $8.19. 686,557 shares of the company's stock were exchanged, compared to its average volume of 1,178,285. REGENXBIO has a twelve month low of $7.14 and a twelve month high of $28.80. The stock has a fifty day moving average of $9.07 and a 200-day moving average of $10.77. The firm has a market cap of $405.77 million, a PE ratio of -1.63 and a beta of 1.28.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.